Hexapeptide-9

The six-residue hexapeptide-9 sequence mirrors a short motif in human collagen. It is used as a messenger or signal peptide rather than as added collagen itself. Trade names include Collaxyl, and its intended role is cosmetic skin conditioning.

Laboratory and supplier work proposes matrikine signaling to dermal fibroblasts and surface keratinocytes, increasing extracellular-matrix components and supporting the junction between upper and lower skin layers. This provides a rationale for firmer, smoother-looking skin. Those cell findings do not prove collagen rebuilding or equivalent clinical effects in every topical formula.

Hexapeptide-9 is not an FDA-approved medicine. As an ordinary cosmetic ingredient, it does not require the premarket drug-approval process. Cosmetic claims concern appearance and feel; claims to change body structure can instead be regulated as drug claims.

It appears in firming and age-appearance creams or serums for smoother texture, more even-looking tone, firmness and fine lines. Formulas often add hydrating agents and other peptides.

An industry-sponsored randomized controlled study reported wrinkle improvements with a cyclized derivative, not standard hexapeptide-9. Other work evaluates delivery systems or combination products, making the isolated ingredient’s effect difficult to determine. The published record does not identify an independent, well-controlled human trial of ordinary hexapeptide-9 alone, and many supplier efficacy claims remain unpublished.

Cosmetic use is generally considered well tolerated with low irritation potential. Sensitive or reactive skin may still respond adversely to a finished product, so patch testing is sensible.